Jardiance To Change The Game In Diabetes
This article was originally published in Scrip
You may also be interested in...
Eli Lilly leads the way in diabetes and is using its current portfolio to find advantageous opportunities in related therapeutic areas.
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.